Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Adds AstraZeneca to Subscriber Base

NEW YORK, May 8 - Gene Logic said Tuesday AstraZeneca signed a multi-year subscription agreement for its GeneExpress suite of databases and GeneExpress 2000 data mining, analysis, and visualization software platform.

" As AstraZeneca Discovery continues to expand its genetic and genomic analysis capabilities, & access to this information will allow our scientists to view the results of their own expression experiments from a much broader perspective," John Stageman, AstraZeneca vice president of enabling science and technology, said in a statement.

" The GeneExpress Suite will integrate well into our sophisticated internal bioinformatics platform which links public, proprietary, and project data together and which is provided on the desktops of all our bioscientists worldwide," he said.

AstraZeneca plans to make Gene Logic's products available to researchers in its drug discovery and development programs.

The GeneExpress suite includes two modules: BioExpress, which consists of gene expression and associated clinical information from normal and diseased human tissues, and ToxExpress, which includes a reference library of toxicity markers derived from examination of known toxic compounds in rodent model systems and across human and rat primary cell lines.

The deal raises Gene Logic's subscriber base to 17, according to the company. Financial terms of the subscription agreement were not disclosed.

Also this year, Gene Logic has signed on two Japanese companies, Sumitomo Pharmaceuticals and Sankyo, as subscribers to the full GeneExpress suite and added IDEC Pharmaceuticals and Genentech as subscribers to its database subsets. 

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.